|
| 36151773 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. | Cancer Med | 2023 |
| 36250964 | Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. | Pediatr Blood Cancer | 2023 |
| 36302496 | Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. | Int J Radiat Oncol Biol Phys | 2023 |
| 36288393 | Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). | Clin Cancer Res | 2023 |
| 36151773 | A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. | Cancer Med | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37651654 | Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. | J Clin Oncol | 2023 |
| 37956387 | Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. | JCO Clin Cancer Inform | 2023 |
| 37058010 | Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). | Clin Cancer Res | 2023 |
| 36669140 | Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37956387 | Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. | JCO Clin Cancer Inform | 2023 |
| 37651654 | Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. | J Clin Oncol | 2023 |
| 37058010 | Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). | Clin Cancer Res | 2023 |
| 36669140 | Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 36250964 | Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. | Pediatr Blood Cancer | 2023 |
| 36302496 | Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. | Int J Radiat Oncol Biol Phys | 2023 |
| 36288393 | Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). | Clin Cancer Res | 2023 |
| 35027427 | Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. | J Immunother Cancer | 2022 |
| 35657346 | Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2022 |
| 35809374 | Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. | Eur J Cancer | 2022 |
| 36203573 | IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. | Front Immunol | 2022 |
| 35727602 | Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. | Clin Cancer Res | 2022 |
| 36115869 | An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. | NPJ Precis Oncol | 2022 |
| 36585406 | Author Correction: Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 36481668 | Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 35312779 | Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. | Mol Cancer Ther | 2022 |
| 35027427 | Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. | J Immunother Cancer | 2022 |
| 35809374 | Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. | Eur J Cancer | 2022 |
| 35727602 | Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma. | Clin Cancer Res | 2022 |
| 35657346 | Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2022 |
| 36585406 | Author Correction: Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 36481668 | Osteosarcoma. | Nat Rev Dis Primers | 2022 |
| 36203573 | IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. | Front Immunol | 2022 |
| 36115869 | An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. | NPJ Precis Oncol | 2022 |
| 35312779 | Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. | Mol Cancer Ther | 2022 |
| 32804009 | Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. | Pediatr Hematol Oncol | 2021 |
| 34021120 | Wnt/ÿ-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells. | Cell Death Dis | 2021 |
| 33619171 | The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. | Clin Cancer Res | 2021 |
| 33769463 | Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. | Arch Pathol Lab Med | 2021 |
| 33603563 | Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. | Sarcoma | 2021 |
| 34137164 | Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. | Pediatr Blood Cancer | 2021 |
| 34131316 | Advancing therapy for osteosarcoma. | Nat Rev Clin Oncol | 2021 |
| 33594717 | The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma. | Ann N Y Acad Sci | 2021 |
| 33298592 | ABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. | Mol Cancer Ther | 2021 |
| 32804009 | Initial <i>in vivo</i> testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. | Pediatr Hematol Oncol | 2021 |
| 33408328 | Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. | Cancer Gene Ther | 2021 |
| 34453478 | In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). | Pediatr Blood Cancer | 2021 |
| 34496122 | Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2021 |
| 34652968 | Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. | J Clin Oncol | 2021 |